Organogenesis Holdings Inc. (ORGO) Stock Price & Analysis
Organogenesis Holdings Inc. (ORGO) fell 1.65% to USD 2.39 as of July 25, 2026 at 07:23 UTC, according to Nexqual real-time market data.
ORGO last closed at USD 2.43; the session ranged USD 2.32–2.44 on volume of 1,165,340 shares. Market capitalization is $307.53M, with a 52-week range of USD 2.04–7.08 (NCM). Source: Nexqual, July 25, 2026 at 07:23 UTC.
Key Statistics (as of July 25, 2026 at 07:23 UTC)
| Price | USD 2.39 |
|---|---|
| Change | ▼ 1.65% (down) |
| Previous Close | USD 2.43 |
| Open | USD 2.43 |
| Day Range | USD 2.32 – 2.44 |
| 52-Week Range | USD 2.04 – 7.08 |
| Volume | 1,165,340 shares |
| Market Cap | $307.53M |
| Exchange | NCM |
Technical Analysis (ORGO)
Nexqual's technical model rates ORGO "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 07:23 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.39 (neutral) |
| vs SMA50 | Below (USD 2.47) |
| MACD | 0.01 (positive) |
Analyst Ratings (ORGO)
Wall Street analysts rate ORGO "Hold" based on 1 analysts, with a mean price target of USD 3 (range USD 3–3), per Nexqual as of July 25, 2026 at 07:23 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 3 |
| High Target | USD 3 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 0 / 2 / 0 |
Earnings (ORGO)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.35 |
| Revenue Estimate | $54.25M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.34 vs est -0.29 ▼ miss |
| 2025-12-31 | USD 0.4 vs est 0.21 ▲ beat |
| 2025-09-30 | USD 0.18 vs est 0.07 ▲ beat |
| 2025-06-30 | USD -0.06 vs est -0.01 ▼ miss |
Source: Nexqual, July 25, 2026 at 07:23 UTC.
Financials & Fundamentals (ORGO)
| Total Revenue | $514.70M |
|---|---|
| Revenue Growth (YoY) | -57.10% |
| Gross Margin | +73.89% |
| Operating Margin | -174.69% |
| Profit Margin | +0.53% |
| ROE | +0.73% |
| Debt / Equity | 18.58 |
| Current Ratio | 3.53 |
| Total Cash | $91.38M |
| Total Debt | $70.86M |
| Free Cash Flow | $21.21M |
Source: Nexqual, July 25, 2026 at 07:23 UTC.
Financial Health Score (ORGO)
Nexqual rates Organogenesis Holdings Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:23 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $91M cash vs $71M debt, net cash position |
| Cash Flow | Mixed — FCF $21M, slim 3.8% margin |
| Efficiency | Weak — ROE 1%, ROA 2.1% |
Ownership (ORGO)
| Insider Ownership | +47.46% |
|---|---|
| Institutional Ownership | +49.29% |
| Shares Outstanding | 128.67M |
| Float | 57.38M |
| Short % of Float | +16.05% |
Source: Nexqual, July 25, 2026 at 07:23 UTC.
Leadership (ORGO)
Organogenesis Holdings Inc. is led by Gary S. Gillheeney (age 70), President, CEO, Chair of the Board, per Nexqual as of July 25, 2026 at 07:23 UTC.
| President, CEO, Chair of the Board | Gary S. Gillheeney (age 70) |
|---|---|
| Chief Financial Officer | David C. Francisco (age 59) |
| Chief Operating Officer | Patrick Bilbo (age 63) |
Major Backers & Investors (ORGO)
Notable institutional backers of Organogenesis Holdings Inc. include Morgan Stanley, Soleus Capital Management, L.P., First Light Asset Management, LLC, according to Nexqual as of July 25, 2026 at 07:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 9.03% |
| Soleus Capital Management, L.P. | 7.84% |
| First Light Asset Management, LLC | 2.72% |
| Shaw D.E. & Co., Inc. | 1.79% |
| Assenagon Asset Management S.A. | 1.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.53% |
| Vanguard Group | 4.84% |
| Dimensional Fund Advisors | 2.57% |
| Geode Capital | 1.39% |
| Deutsche Bank AG | 1.33% |
Source: Nexqual, July 25, 2026 at 07:23 UTC.
From Organogenesis Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
- The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing.
- In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products.
- The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STRO | Sutro Biopharma, Inc. | USD 22.88 | ▼ 2.22% |
| FULC | Fulcrum Therapeutics, Inc. | USD 3.72 | ▲ 0.54% |
| PTGX | Protagonist Therapeutics, Inc. | USD 136.11 | ▲ 0.49% |
| QTRX | Quanterix Corporation | USD 3.67 | ▼ 4.43% |
| SLDB | Solid Biosciences Inc. | USD 7.83 | ▼ 3.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:23 UTC. This page is informational and not investment advice.